Intellia Therapeutics Head office building

Press Releases

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Read More

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Read More

Upcoming
Events

More events are coming soon.

ENVIRONMENTAL,
SOCIAL &
GOVERNANCE (ESG)

OUR COMMITMENT Intellia’s objective is to build a sustainable company delivering on our commitment to the patients we serve, our employees, community, environment and shareholders.

We believe Environmental, Social and Governance (ESG) principles support long term value creation. Throughout this report, we have highlighted our approach to managing risk and taking advantage of opportunities in key ESG areas the areas that are most relevant to the long term sustainability of our company.

Stock Information

Minimum 15 minutes delayed. Source: